Centessa Pharmaceuticals plc

CNTA

NASDAQ

Healthcare

Biotechnology

Altrincham, GB77 employeescentessa.com

$39.72

-0.14(-0.36%)

Mkt Cap $5.3B

$10.71

$39.86

52-Week Range

At a Glance

AI-generated

Centessa Pharmaceuticals generated $15.0 million in revenue during FY2025, marking its first revenue contribution, while net losses narrowed year-over-year due to lower R&D expenses and non-operating income from foreign currency fluctuations.

Revenue breakdown: Reportable Segment (100%).

8-K

Centessa Pharmaceuticals plc entered into a definitive agreement to be acquired by Eli Lilly and Company for $38.00 per share in cash plus a contingent value right worth up to $9.00 per share, subject to shareholder and regulatory approvals.

$5.3B

Market Cap

$15M

Revenue

-$243M

Net Income

Employees77

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($15M)

Activity

What Changed Recently

Management Change

Feb 12, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously

Management Change

Jan 6, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously

Material Agreement

Mar 30, 2026

by reference. | Item 7.01 | Regulation FD Disclosure. | |---|---| On March 31, 2026, the Company and Parent issued a joint press release announcing the executio

Company Profile

CIK0001847903

ISINUS1523091007

CUSIP152309100

Phone44 203 9206789

Address1 Ashley Road, Altrincham, WA14 2DT, GB

SEC EDGAR